Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis

Massimo Cugno, Francesca Ingegnoli, Roberta Gualtierotti, Flavio Fantini

Research output: Contribution to journalArticle

Abstract

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that affects about 1% of the adult population. RA sufferers not only have a high chronic disease burden, but may also experience increased cardiovascular disease (CVD) and mortality as the prevalence of myocardial infarction (MI) is 4 times higher in RA patients than in general population, and there is ample evidence showing that coagulation processes are active in RA. Fibrin accumulation in the synovium is one of the most striking pathological features of rheumatoid synovitis and characteristic RA antibodies such as anti-citrullinated protein antibodies (ACPA) can cross-react with epitopes exposed on fibrin and fibrinogen molecules, and thus impair fibrinolysis. The inflammation, coagulation and fibrinolytic systems are modulated by a common mechanism that includes the involvement of proinflammatory cytokines, such as tumour necrosis factor-α (TNF-α) and interleukin 6 (IL-6). It has long been recognised that extensive cross-talk takes place between the coagulation pathway and the inflammatory process at various levels, and there is growing evidence that this interaction may be relevant to arthritis. Large-scale, long-term studies have shown that anti-TNF-α treatment improves the clinical and laboratory measures of disease activity, and reduces local and systemic inflammation. TNF-α blockade may therefore also reduce the impaired coagulation and cardiovascular risk associated with RA. This review provides an overview of the pathophysiological role of TNF-α in thrombotic mechanisms and the evidence so far available indicating that anti-TNF-α treatment can modify cardiovascular risk in RA.

Original languageEnglish
Pages (from-to)285-292
Number of pages8
JournalCurrent Vascular Pharmacology
Volume8
Issue number2
DOIs
Publication statusPublished - Mar 2010

Fingerprint

Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Fibrin
Therapeutics
Inflammation
Synovitis
Synovial Membrane
Antibodies
Fibrinolysis
Fibrinogen
Population
Arthritis
Epitopes
Interleukin-6
Chronic Disease
Cardiovascular Diseases
Myocardial Infarction
Cytokines
Mortality
Proteins

Keywords

  • Cardiovascular disease
  • Inflammation
  • Rheumatoid arthritis
  • Tumor necrosis factor-alpha

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis. / Cugno, Massimo; Ingegnoli, Francesca; Gualtierotti, Roberta; Fantini, Flavio.

In: Current Vascular Pharmacology, Vol. 8, No. 2, 03.2010, p. 285-292.

Research output: Contribution to journalArticle

@article{ba7d5978ca9c465a8f3000baf8bd1189,
title = "Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis",
abstract = "Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that affects about 1{\%} of the adult population. RA sufferers not only have a high chronic disease burden, but may also experience increased cardiovascular disease (CVD) and mortality as the prevalence of myocardial infarction (MI) is 4 times higher in RA patients than in general population, and there is ample evidence showing that coagulation processes are active in RA. Fibrin accumulation in the synovium is one of the most striking pathological features of rheumatoid synovitis and characteristic RA antibodies such as anti-citrullinated protein antibodies (ACPA) can cross-react with epitopes exposed on fibrin and fibrinogen molecules, and thus impair fibrinolysis. The inflammation, coagulation and fibrinolytic systems are modulated by a common mechanism that includes the involvement of proinflammatory cytokines, such as tumour necrosis factor-α (TNF-α) and interleukin 6 (IL-6). It has long been recognised that extensive cross-talk takes place between the coagulation pathway and the inflammatory process at various levels, and there is growing evidence that this interaction may be relevant to arthritis. Large-scale, long-term studies have shown that anti-TNF-α treatment improves the clinical and laboratory measures of disease activity, and reduces local and systemic inflammation. TNF-α blockade may therefore also reduce the impaired coagulation and cardiovascular risk associated with RA. This review provides an overview of the pathophysiological role of TNF-α in thrombotic mechanisms and the evidence so far available indicating that anti-TNF-α treatment can modify cardiovascular risk in RA.",
keywords = "Cardiovascular disease, Inflammation, Rheumatoid arthritis, Tumor necrosis factor-alpha",
author = "Massimo Cugno and Francesca Ingegnoli and Roberta Gualtierotti and Flavio Fantini",
year = "2010",
month = "3",
doi = "10.2174/157016110790886965",
language = "English",
volume = "8",
pages = "285--292",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis

AU - Cugno, Massimo

AU - Ingegnoli, Francesca

AU - Gualtierotti, Roberta

AU - Fantini, Flavio

PY - 2010/3

Y1 - 2010/3

N2 - Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that affects about 1% of the adult population. RA sufferers not only have a high chronic disease burden, but may also experience increased cardiovascular disease (CVD) and mortality as the prevalence of myocardial infarction (MI) is 4 times higher in RA patients than in general population, and there is ample evidence showing that coagulation processes are active in RA. Fibrin accumulation in the synovium is one of the most striking pathological features of rheumatoid synovitis and characteristic RA antibodies such as anti-citrullinated protein antibodies (ACPA) can cross-react with epitopes exposed on fibrin and fibrinogen molecules, and thus impair fibrinolysis. The inflammation, coagulation and fibrinolytic systems are modulated by a common mechanism that includes the involvement of proinflammatory cytokines, such as tumour necrosis factor-α (TNF-α) and interleukin 6 (IL-6). It has long been recognised that extensive cross-talk takes place between the coagulation pathway and the inflammatory process at various levels, and there is growing evidence that this interaction may be relevant to arthritis. Large-scale, long-term studies have shown that anti-TNF-α treatment improves the clinical and laboratory measures of disease activity, and reduces local and systemic inflammation. TNF-α blockade may therefore also reduce the impaired coagulation and cardiovascular risk associated with RA. This review provides an overview of the pathophysiological role of TNF-α in thrombotic mechanisms and the evidence so far available indicating that anti-TNF-α treatment can modify cardiovascular risk in RA.

AB - Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that affects about 1% of the adult population. RA sufferers not only have a high chronic disease burden, but may also experience increased cardiovascular disease (CVD) and mortality as the prevalence of myocardial infarction (MI) is 4 times higher in RA patients than in general population, and there is ample evidence showing that coagulation processes are active in RA. Fibrin accumulation in the synovium is one of the most striking pathological features of rheumatoid synovitis and characteristic RA antibodies such as anti-citrullinated protein antibodies (ACPA) can cross-react with epitopes exposed on fibrin and fibrinogen molecules, and thus impair fibrinolysis. The inflammation, coagulation and fibrinolytic systems are modulated by a common mechanism that includes the involvement of proinflammatory cytokines, such as tumour necrosis factor-α (TNF-α) and interleukin 6 (IL-6). It has long been recognised that extensive cross-talk takes place between the coagulation pathway and the inflammatory process at various levels, and there is growing evidence that this interaction may be relevant to arthritis. Large-scale, long-term studies have shown that anti-TNF-α treatment improves the clinical and laboratory measures of disease activity, and reduces local and systemic inflammation. TNF-α blockade may therefore also reduce the impaired coagulation and cardiovascular risk associated with RA. This review provides an overview of the pathophysiological role of TNF-α in thrombotic mechanisms and the evidence so far available indicating that anti-TNF-α treatment can modify cardiovascular risk in RA.

KW - Cardiovascular disease

KW - Inflammation

KW - Rheumatoid arthritis

KW - Tumor necrosis factor-alpha

UR - http://www.scopus.com/inward/record.url?scp=77949505523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949505523&partnerID=8YFLogxK

U2 - 10.2174/157016110790886965

DO - 10.2174/157016110790886965

M3 - Article

C2 - 19485909

AN - SCOPUS:77949505523

VL - 8

SP - 285

EP - 292

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 2

ER -